We are live on ! Find out more
ORKA icon

Oruka Therapeutics
ORKA

15 hedge funds and large institutions have $12.4M invested in Oruka Therapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

9.42% less ownership

Funds ownership: 63.1% → 53.67% (-9.4%)

12% less funds holding

Funds holding: 17 → 15 (-2)

84% less capital inflows, than outflows

Capital inflows: $180K | Capital outflows: $1.15M

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royce & Associates
Royce & Associates
New York
+$80.4K
2
BlackRock
BlackRock
New York
+$41.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$29.6K
4
Northern Trust
Northern Trust
Illinois
+$28.5K
5
Deutsche Bank
Deutsche Bank
Germany
+$558

Top Sellers

Rank Fund Capital Flow
1
RA Capital Management
RA Capital Management
Massachusetts
-$662K
2
Aveo Capital Partners
Aveo Capital Partners
Colorado
-$474K
3
Goldman Sachs
Goldman Sachs
New York
-$9.49K
4
UBS Group
UBS Group
Switzerland
-$2.79K

ORKA Hedge Fund Activity: Q1 2017 in Review

15 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2017, worth a combined $12.4M — down 24% from $16.3M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ORKA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $80.4K. The largest seller was RA Capital Management, exiting entirely with an estimated $662K sold.

  • 15 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2017, down from 17 in Q4 2016.
  • Funds reported $12.4M of Oruka Therapeutics stock for Q1 2017, down 24% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q1 2017 and 2 closed out, a net change of +1 holder.
  • The largest Oruka Therapeutics buyer in Q1 2017 was Royce & Associates, an estimated $80.4K added.
  • The largest Oruka Therapeutics seller in Q1 2017 was RA Capital Management, an estimated $662K sold.

Based on aggregated 13F filings for Q1 2017.